Current treatment status-Did not start treatment yet Posts on Medivizor
Navigation Menu

Current treatment status-Did not start treatment yet Posts on Medivizor

Evaluating A+AVD for patients with newly diagnosed advanced Hodgkin lymphoma

Posted by on Feb 17, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of brentuximab vedotin (Adcetris) plus chemotherapy for patients with advanced (stage 3 – 4) Hodgkin’s lymphoma (HL). This study concluded that this treatment is effective for these patients. Some background The most commonly used frontline chemotherapy regimen for advanced HL...

Read More

Risk of hepatitis B reactivation in patients with lymphomas receiving obinutuzumab or rituximab

Posted by on Jan 3, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the risk of reactivating hepatitis B (HBV) infection in patients with lymphoma treated with obinutuzumab (Gazyva) or rituximab (Rituxan). Researchers found that HBV infection was reactivated in some of these patients but treatment options are available. Some background Lymphoma is a cancer of the immune system....

Read More

Lenalidomide and dexamethasone in the treatment of chronic lymphocytic leukemia

Posted by on Dec 22, 2018 in Leukemia | 0 comments

In a nutshell The study looked at the safety and effectiveness of adding dexamethasone (Decadron) to lenalidomide (Revlimid) in previously untreated patients with chronic lymphocytic leukemia (CLL). Researchers concluded that lenalidomide plus dexamethasone is an effective treatment for CLL. Some background Chronic lymphocytic leukemia (CLL) is a...

Read More

Evaluating the use of PET scanning after first-line treatment for follicular lymphoma

Posted by on Nov 14, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the value of PET (positron emission tomography) scanning after first-line (primary) chemoimmunotherapy in patients with previously untreated follicular lymphoma (FL). This study concluded that PET scanning is a better imaging technique than CT (computed tomography) for assessing treatment response in these...

Read More

Evaluating rituximab maintenance therapy for elderly patients with follicular lymphoma

Posted by on Oct 30, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of maintenance therapy with rituximab (Rituxan) in elderly patients with newly diagnosed follicular lymphoma (FL). This study concluded that maintenance rituximab treatment improved survival outcomes in these patients in a real-world setting. Some background Chemoimmunotherapy containing rituximab...

Read More

Comparing prostate surgery with radiotherapy and radiotherapy with androgen deprivation therapy for advanced prostate cancer

Posted by on Oct 28, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the long-term effects of two treatment combinations for advanced prostate cancer. This study found that surgery and radiotherapy had improved overall survival in comparison with radiotherapy plus androgen deprivation therapy (ADT) in these patients, but with higher rates of side-effects. Some background...

Read More

Evaluating short-course ABVD chemotherapy in patients with early-stage Hodgkin lymphoma

Posted by on Sep 28, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of short-course (2 cycles) ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy with interim PET scanning in previously untreated patients with early-stage (stage 1 – 2) Hodgkin’s lymphoma (HL). This study concluded that short-course ABVD was effective in the majority of...

Read More

Sequential treatment for patients with chronic lymphocytic leukemia who have received bendamustine

Posted by on Sep 17, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness of obinutuzumab and venetoclax after bendamustine treatment in patients with chronic lymphocytic leukemia (CLL). This study concluded that this sequence of treatment caused no unexpected side effects. It also concluded that the outcomes were comparable to established therapies for CLL. Some...

Read More